Suzanne Schindler, MD
Neurology · Saint Louis, MONPI 1053561266
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,070 of the $29,079 with a category attached, or 89.7%. 6 manufacturers reported payments, led by Eisai Inc. at 44.1% of the total. Reporting peaked in 2024 at $23,578 and has fallen 99.8% since, to $44 in 2025.
Across 21 payments — averaging $1384.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$13K
- Novo Nordisk$11K
- Lilly USA, LLC$4K
- Novo Nordisk AS$2K
- Beckman Coulter, Inc.$67
- Janssen Global Services, LLC$44
Across 1 payment — averaging $2,170,307 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beckman Coulter, Inc.$2.2M
What the payments were for
- Consulting fees$26,07090%
- Travel & lodging$2,2448%
- Food & beverage$7663%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 11 | $12,816 |
| Novo Nordisk | 6 | $10,903 |
| Lilly USA, LLC | 1 | $3,750 |
| Novo Nordisk AS | 1 | $1,500 |
| Beckman Coulter, Inc. | 1 | $67 |
| Janssen Global Services, LLC | 1 | $44 |
How this compares
$29,079 in reported general payments places this provider in the 85th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 17 | $2,078 |
| Donepezil Hcl | 156 | $1,173 |
| Bupropion XlBupropion Hcl | 28 | $1,049 |
| Escitalopram Oxalate | 96 | $1,028 |
| Duloxetine Hcl | 17 | $260 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 23 | $235 |
| Levetiracetam | 11 | $233 |
| Trazodone Hcl | 18 | $219 |
| Quetiapine Fumarate | 11 | $73 |
Paid to pharmacies, not to this prescriber.
Other neurology in Saint Louis
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Robert NaismithSaint Louis$677K
- Arun VaradhacharySaint Louis$273K
- Anne CrossSaint Louis$190K
- David HoltzmanSaint Louis$165K
- Ghazala HayatSaint Louis$155K
- Pratap ChandSaint Louis$139K
- Lee TempelSaint Louis$121K
- Salim ChahinSaint Louis$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.